If HEB get FDA approval in the next weeks the stock will range between $10-$30 from its current $3 range. I personally purchased last week at $2.65 and thought I was in a little late. But if FDA approval fails the stock could fall below $1.
With the World Health Organization (WHO) officially declaring the flu a pandemic of phase 6, one company looking to make waves is Hemispherx BioPharma (AMEX:HEB). Analysis from http://www.StocksHaven.com
Hemispherx has recently been in limbo awaiting FDA decision on the long-awaited treatment for Chronic Fatigue Syndrome (CFS), Ampligen.
Ampligen, also known as poly I:poly C12U, is an experimental immunomodulatory double stranded RNA drug developed by HEMISPHERx Biopharma of Philadelphia, Pennsylvania. Ampligen was first synthesized in the 1970s and has been proposed and tested as a treatment for many illnesses, but primarily chronic fatigue syndrome (ME/CFS) and acquired immunodeficiency syndrome (AIDS).
Summary of articles
Identifying Fact vs. Fiction on Hemispherx’s Ampligen
Hemispherx Ampligen Combats H5N1
Post Approval Hemispherx Ampligen PPS Evaluation
Conference Call - Hemispherx Responds to TheStreet.com
Hemispherx Fights Back Against Feuerstein
Conference Call - Hemispherx BioPharma, Inc.
Taking on influenza
Hemispherx has a broad-based technology platform for confronting the potential of an influenza pandemic, which consists of both preventative (vaccine) components as well as experimental therapeutic interventions. Clinical results from trials conducted in Australia are being evaluated and major vaccine initiatives in Japan are being accelerated in collaboration with the Japanese National Institutes of Health and the Japanese Ministry of Health. According to the Japanese National Institute of Infectious Diseases Scientists Identify Hemispherx Biopharma’s Drug Technology as the “Most Promising Mucosal Adjuvant for Influenza.”
StocksHaven Investments believes the phase 6 declaration presents a strong buy signal for Hemispherx BioPharma (AMEX:HEB), within both the short-term and long-term.